Ovarian cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• BRCA1 20
• BRCA2 13
• PARP 27
• TP53 6
• PD-1 12
• AKT 2
• HER2 16
• PD-L1 7
• PI3K 3
• STAT3 1
• mTOR 0
• VEGF 7
• KRAS 6
• EGFR 3
• PTEN 2
• MAPK 0
• CTNNB1 0
• FAK 1
• MYC 0
• NRF2 0
• CTLA-4 6
• ERK 1
• JAK 0
• STING 0
• GPX4 0
• HIF-1 0
• MEK 1
• TROP2 4
• PALB2 5
• B7-H3 7
• CDK4/6 4
• ATM 1
• CD47 0
• IL-6 0
• PIK3CA 3
• EZH2 1
• JNK 0
• YAP 0
• BCL-2 0
• BRAF 4
• CXCR4 0
• HDAC 0
• PPAR 0
• AMPK 0
• ARID1A 3
• AXL 1
• COX-2 2
• NMDA 0
• TIGIT 0
• AR 0
• CD40 1
• HER3 1
• HMGB1 0
• KEAP1 1
• METTL3 0
• RAS 0
• TLR4 0
• FGFR 0
• PINK1 0
• PKM2 0

24 of 44+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · F31

  The role of p16 expression in sensitivity and resistance to CDK2 inhibitors

  University of Colorado· Boulder, United States· US$43,146 awarded in fiscal year 2026· until Sept 2029

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, United States· US$768,308 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · R01

  Overcoming ovarian cancer chemoresistance by co-targeting senescence and apoptosis

  Harvard University D/B/A Harvard School of Public Health· Boston, United States· US$390,447 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Immune Dysfunction, Social Determinants of Health, and Ovarian Cancer Outcome Differences

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$674,142 awarded in fiscal year 2026· until Aug 2031

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, United States· US$377,257 awarded in fiscal year 2026· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Decoding the Lipidome of Adipose-Derived Extracellular Vesicles in Ovarian Cancer: Mechanistic Insight into Tumor-Adipose Crosstalk (Lipid-Ex)

  Philipps Universitaet Marburg· Marburg, Germany· EU contribution €202,125· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Precision Reasoning In Multimodal Ovarian cancer (PRIMO)

  Institut Regional du Cancer de Montpellier· Montpellier Cedex 5, France· EU contribution €150,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  CAR T ceLls with Anti-exhaUstion Device for Immunotherapy Advancement (CLAUDIA)

  Fondazione Istituto Italiano di Tecnologia· Genova, Italy· EU contribution €150,000· until Mar 2028

• European Commission (Horizon Europe) · HORIZON-EIC

  Interpretable Multimodal Predictive Agents and Digital Twins for Ovarian Cancer (IMPACT-OC)

  Danube Private University Gmbh· Krems-Stein, Austria· EU contribution €3,977,586· until Sept 2030· 5 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  A Novel Phase-2a Clinical Trial for a Next-Generation Oncolytic Immunotherapy Targeting Platinum-Resistant Ovarian Cancer (OCTOPOD-Ph2a)

  Theolytics Ltd· Oxford, United Kingdom· EU contribution €7,998,791· until May 2029· 3 countries

10 of 662 running projects, newest first. Listed amounts together: US$367.4m + €54.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

  NCT07060365· AstraZeneca· Updated 3 Apr 2026

  “The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns.”Registry text, quoted unchanged. Source

• Terminated

  NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

  NCT05252390· Nuvation Bio Inc.· Updated 6 Nov 2025

  “The Sponsor has achieved its objectives.”Registry text, quoted unchanged. Source

• Terminated

  Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

  NCT04182516· Nerviano Medical Sciences· Updated 19 Sept 2024

  “The study closure is related to sponsor decision to shift towards the clinical development of NMS-03305293 in combination in a broader range of indication and not based on emerging safety or efficacy concerns.”Registry text, quoted unchanged. Source

• Withdrawn

  Breast Cancer BRCA1 Carriers: a Pilot Study

  NCT05062174· Indiana University· Updated 15 Dec 2022

  “PI decision to cancel research”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

  NCT06914726· HealthPartners Institute· Source

• A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

  NCT07060365· AstraZeneca· Source

• Letrozole in Preventing Breast Cancer in Postmenopausal Women With a BRCA1 or BRCA2 Mutation

  NCT00673335· UNICANCER· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 48
• Organoids 19
• Mendelian Randomization Analysis 30
• CRISPR-Cas Systems 15
• Gene Expression Profiling 126
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 6
• Exome Sequencing 11
• Proteomics 62
• Metabolomics 17
• Mass Spectrometry 6
• Flow Cytometry 26
• Immunohistochemistry 95
• Liquid Biopsy 15
• Circulating Tumor DNA 14
• Xenograft Model Antitumor Assays 234
• Positron-Emission Tomography 9
• Magnetic Resonance Imaging 57
• Machine Learning 60
• Deep Learning 36
• Cohort Studies 105
• Genome-Wide Association Study 27

• Si-scRNA-seq: Enabling ambient-stable single-cell transcriptomics through spatially confined biosilicification.

  Proc Natl Acad Sci U S A, Oct 2026

• Single-cell sequencing reveals immune networks and metabolic reprogramming in gynecological malignancies.

  Front Immunol, Oct 2026

• Functional single-cell omics in gynecological cancers immunotherapy: from heterogeneity dissection to clinical translation.

  Front Immunol, Oct 2026

• Ferroptosis and nutrient-metabolic pathway genes in ovarian cancer: integrated bulk and single-cell analysis of Iron-metabolic programs, immune-marker enrichment, and prognosis.

  Front Public Health, Oct 2026

• Characterizing intra- and intertumor heterogeneity in ovarian high-grade serous carcinoma subtypes using single-cell and spatial transcriptomics.

  Genome Res, Oct 2026

• Tumor-intrinsic IFNγ signaling and niche adaptation drive early colonization in ovarian cancer metastasis.

  Nat Commun, Sept 2026

• Single-Cell Transcriptomic Analysis Reveals Ferroptosis-Related Signatures and Tumor Microenvironment Heterogeneity in Epithelial Ovarian Cancer.

  Cancer Med, Sept 2026

• iDCF: Interpretable deconvolution of cell fractions via biologically-informed deep learning using scRNA-seq data.

  PLoS Comput Biol, Aug 2026

• Combining network toxicology, single-cell RNA sequencing, and in vitro/in vivo experimental models reveals MMP9 as the key mediator of 27-hydroxycholesterol-driven ovarian cancer.

  Chem Biol Interact, Aug 2026

• Quantitative Single-Cell Multielemental Analysis Using Metal-Loaded Microparticles: toward a Universal Quantification Workflow in Mass Cytometry.

  Anal Chem, Aug 2026

See which targets of this disease your abstract mentions, and go to the people working on them.